Voiding dysfunction of men is associated with metabolic syndrome

Korean Journal of Urology

Volumn 47, Issue 3, 2006, Pages 257-262

  Kim, Jae Hun ^a   Shim, Bong Suk ^a   Kim, Jae Sik ^a   Hong, Young Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Benign prostatic hyperplasia; Metabolic syndrome X; Urination disorder

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICTURITION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; QUALITY OF LIFE; RESIDUAL URINE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; URINE FLOW RATE;

EID: 33744828681     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2006.47.3.257     Document Type: Article

References (30)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
2. Fuster V, Pearson TA. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957-1047
3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
5. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994;15(Suppl C):78-81
6. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297-301
7. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-3
8. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62
9. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39:151-8
10. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004;52: 291-4
11. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003; 22(Suppl 2):35-43
12. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Excutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
15. Western Pacific Regional Office of the World Health Organization, The International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia, 2000. http://www.obesit yasiapacific.com
16. Nugent AP. The metabolic syndrome. BNF Nutr Bull 2004; 29:36-43
17. Lym YL, Hwang SW, Shim HJ, Oh EH, Chang YS, Cho BL. Prevalence and risk factors of the metabolic syndrome as defined by NCEP-ATP III. J Korean Acad Fam Med 2003;24: 135-43
18. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90
19. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32(Suppl):465A
20. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163: 1725-9
21. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23
22. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604
23. Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 2004;27:665-9
24. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569-74
25. Saito M, Ohmura M, Kondo A. Effect of ageing on blood flow to the bladder and bladder function. Urol Int 1999;62:93-8
26. Lau DH, Kommu S, Mikhailidis DP, Morgan RJ, Mumtaz FH. Re: the prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2005;173:1050
27. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477-86
28. Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992;5: 827-31
29. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31: 415-20
30. Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989;86:14-8